PDC BIOTECH
PDC Biotech GmbH (PDC) is a private biopharmaceutical company developing innovative therapeutics for the treatment of preterm labour and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. The primary focus for the company is the development of a pipeline of products which are antagonists of the receptor for prostaglandin F2รยฑ (FP receptor). PDC has licensed exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc. (www.theratech.com) which include both peptides (compounds composed of at least two amino acids) and peptidomimetics (peptide-like compounds).
PDC BIOTECH
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.pdcbiotech.com
Total Employee:
1+
Status:
Active
Contact:
43 1 8900077
Email Addresses:
[email protected]
Total Funding:
5.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible GoDaddy DNS Google Google Cloud CloudFront OpenResty Google Adsense Google Cloud Global Multi-Region AdBlock Acceptable Ads
Founder
Investors List
Andera Partners
Andera Partners investment in Series A - PDC Biotech
MIG
MIG investment in Series A - PDC Biotech
Official Site Inspections
http://www.pdcbiotech.com
- Host name: li647-167.members.linode.com
- IP address: 198.58.118.167
- Location: Dallas United States
- Latitude: 32.7787
- Longitude: -96.8217
- Metro Code: 623
- Timezone: America/Chicago
- Postal: 75270
More informations about "PDC Biotech"
PDS Biotech - Leadership Team
Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing โฆSee details»
PDS Biotechnology Corporation - Crunchbase Company Profile
PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, โฆSee details»
PDS Biotech - Investor Relations
Nov 14, 2024 PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients worldwide. We are โฆSee details»
PDS Biotechnology - Overview, News & Similar companies
Jan 22, 2024 PDS Biotechnology contact info: Phone number: (800) 208-3343 Website: www.pdsbiotech.com What does PDS Biotechnology do? PDS Biotechnology Corporation is a โฆSee details»
PDS Biotechnology Company Overview, Contact Details
Aug 24, 2022 Pdsbiotech hired Lars Boesgaard as Chief Financial Officer on Nov 28th '23. PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation โฆSee details»
PDS Biotechnology - LinkedIn
PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating โฆSee details»
PDS Biotechnology Corporation (PDSB) - Stock Analysis
Dec 13, 2024 Ticker Symbol: PDSB: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001472091: CUSIP Number: 70465T107: ISIN โฆSee details»
PDS Biotech - About
PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients worldwide. We are also committed to โฆSee details»
PDS Biotech Provides Business Update and Reports Second โฆ
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (โPDS Biotechโ or the โCompanyโ), a late-stage immunotherapy company โฆSee details»
PDS Biotechnology - Craft
PDS Biotechnology has 5 employees across 3 locations and $2.04 m in total funding,. See insights on PDS Biotechnology including office locations, competitors, revenue, financials, โฆSee details»
PDS Biotech Provides Business Update and Reports First Quarter โฆ
May 15, 2024 The press release will be available in the Investor Relations section of the Companyโs website at www.pdsbiotech.com. Recent Developments. Hosted a Key Opinion โฆSee details»
PDS Biotechnology Corp. (PDS Biotechnology Corp.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
For more information, please visit www.pdsbiotech.com. Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section โฆSee details»
PDS Biotech Completes $35 Million Financing Agreement Led
Aug 24, 2022 Email: [email protected]. Nicole Jones CG Capital Phone: +1 (404) 736-3838 Email: [email protected]. Tags Biotechnology ONCOLOGY versamune. Related โฆSee details»
CORPORATE OVERVIEW - PDS Biotech
Nasdaq: PDSB Versamune® is designed to induce a robust and targeted anti-tumor response in vivo when administered with a tumor-associated antigen 5 References: Gandhapudi SK, et al. โฆSee details»
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive โฆ
Aug 1, 2024 Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- โฆSee details»
PDS Biotechnology Corporation (PDSB) - Stock Analysis
5 days ago Website https://www.pdsbiotech.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 3 analysts, the average rating for PDSB โฆSee details»
CORPORATE OVERVIEW - PDS Biotech
Nasdaq: PDSB 3 PDS Biotechโs Versamune®-based immunotherapies promote a powerful in vivo tumor-specific CD8+ killer T-cell response Generate a strong CD8+ T-cell memory response โฆSee details»
Nominating and Corporate Governance Committee Charter
Title: Microsoft Word - Nominating and Corporate Governance Committee Charter (for distribution to the committee 4-28-16).doc Created Date: 20190626130412ZSee details»
PDS Biotech Announces Presentation of Preliminary PDS0101 โฆ
FLORHAM PARK, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of โฆSee details»